BR112022020278A2 - Compostos inibidores de chk1, formas sólidas cristalinas, processos para preparar os mesmos e composição farmacêutica - Google Patents
Compostos inibidores de chk1, formas sólidas cristalinas, processos para preparar os mesmos e composição farmacêuticaInfo
- Publication number
- BR112022020278A2 BR112022020278A2 BR112022020278A BR112022020278A BR112022020278A2 BR 112022020278 A2 BR112022020278 A2 BR 112022020278A2 BR 112022020278 A BR112022020278 A BR 112022020278A BR 112022020278 A BR112022020278 A BR 112022020278A BR 112022020278 A2 BR112022020278 A2 BR 112022020278A2
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- chk1
- preparing
- pharmaceutical composition
- crystalline forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006305P | 2020-04-07 | 2020-04-07 | |
| PCT/US2021/025977 WO2021207210A1 (en) | 2020-04-07 | 2021-04-06 | Methods for synthesis of chk1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020278A2 true BR112022020278A2 (pt) | 2022-12-06 |
Family
ID=78024095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020278A BR112022020278A2 (pt) | 2020-04-07 | 2021-04-06 | Compostos inibidores de chk1, formas sólidas cristalinas, processos para preparar os mesmos e composição farmacêutica |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12606550B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132922A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023523165A (cg-RX-API-DMAC7.html) |
| CN (2) | CN120441567A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020278A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174222A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021207210A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120441567A (zh) | 2020-04-07 | 2025-08-08 | Crt先锋基金有限公司 | Chk1抑制剂的合成方法 |
| WO2026108769A1 (en) * | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773778A (en) | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| IL150524A0 (en) | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| JP4637481B2 (ja) | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| CA2464934A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003243318A1 (en) | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| AU2004260689B8 (en) | 2003-07-29 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005034869A2 (en) | 2003-10-08 | 2005-04-21 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005037825A2 (en) | 2003-10-14 | 2005-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| WO2005037285A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| US20050096324A1 (en) | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
| US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| US7642354B2 (en) | 2004-04-13 | 2010-01-05 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| CN1243033C (zh) | 2004-07-15 | 2006-02-22 | 合肥工业大学 | 一种通过内增韧制备薄膜级聚l-乳酸共聚物的方法 |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101189239A (zh) | 2005-04-28 | 2008-05-28 | 休普基因公司 | 蛋白激酶抑制剂 |
| EP1899322B1 (en) | 2005-06-28 | 2009-09-02 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| PE20070543A1 (es) | 2005-10-06 | 2007-06-14 | Schering Corp | Pirazolopirimidinas como inhibidores de protein quinasas |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0616747D0 (en) | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| AU2007338410B2 (en) | 2006-12-27 | 2012-08-16 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
| EP2134689B1 (en) | 2007-03-16 | 2014-04-23 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| RU2009147819A (ru) | 2007-05-25 | 2011-06-27 | Астразенека Аб (Se) | Комбинация ингибиторов снк и parp для лечения злокачественных новообразований |
| US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2009099601A2 (en) | 2008-02-04 | 2009-08-13 | Dana-Farber Cancer Institute, Inc. | Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US8865726B2 (en) * | 2009-09-03 | 2014-10-21 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| US9345705B2 (en) | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| WO2013068755A1 (en) | 2011-11-09 | 2013-05-16 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| CA2860665A1 (en) | 2012-01-05 | 2013-07-11 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
| JP6027230B2 (ja) * | 2012-05-15 | 2016-11-16 | キャンサー・リサーチ・テクノロジー・リミテッド | 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用 |
| CN102675858A (zh) | 2012-05-22 | 2012-09-19 | 同济大学 | 一种具有形状记忆功能可降解泪管栓塞的制备方法 |
| GB201316526D0 (en) | 2013-09-17 | 2013-10-30 | King S College London | Biomarkers |
| WO2015077602A1 (en) | 2013-11-22 | 2015-05-28 | Fred Hutchinson Cancer Research Center | Methods for identifying therapeutic targets and treating and monitoring cancers |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| SG10201913151TA (en) | 2015-09-09 | 2020-03-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Genetic engineering of macrophages for immunotherapy |
| US11725247B2 (en) | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
| WO2018102613A2 (en) | 2016-12-01 | 2018-06-07 | Nantomics, Llc | Tumor antigenicity processing and presentation |
| WO2018191299A1 (en) | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
| MX2019012176A (es) | 2017-04-10 | 2020-02-19 | Sierra Oncology Inc | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. |
| AU2018278336A1 (en) | 2017-06-01 | 2020-01-16 | Crt Pioneer Fund Lp | Biomarkers and patient selection strategies |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER |
| JP2021514979A (ja) | 2018-02-26 | 2021-06-17 | シエラ オンコロジー, インコーポレイテッド | Chk1阻害剤を含む癌の治療方法 |
| CA3135165A1 (en) | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| AU2020274164A1 (en) | 2019-05-14 | 2021-11-25 | Sierra Oncology, Inc. | Methods of treating cancer using Chk1 inhibitors |
| CN120441567A (zh) | 2020-04-07 | 2025-08-08 | Crt先锋基金有限公司 | Chk1抑制剂的合成方法 |
-
2021
- 2021-04-06 CN CN202510460667.8A patent/CN120441567A/zh active Pending
- 2021-04-06 WO PCT/US2021/025977 patent/WO2021207210A1/en not_active Ceased
- 2021-04-06 JP JP2022561181A patent/JP2023523165A/ja active Pending
- 2021-04-06 EP EP21784225.1A patent/EP4132922A4/en active Pending
- 2021-04-06 BR BR112022020278A patent/BR112022020278A2/pt unknown
- 2021-04-06 CA CA3174222A patent/CA3174222A1/en active Pending
- 2021-04-06 US US17/995,564 patent/US12606550B2/en active Active
- 2021-04-06 CN CN202180027747.4A patent/CN115443271A/zh active Pending
-
2026
- 2026-03-02 JP JP2026032793A patent/JP2026097919A/ja active Pending
- 2026-03-20 US US19/573,479 patent/US20260217695A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230150994A1 (en) | 2023-05-18 |
| EP4132922A1 (en) | 2023-02-15 |
| JP2023523165A (ja) | 2023-06-02 |
| US12606550B2 (en) | 2026-04-21 |
| CN120441567A (zh) | 2025-08-08 |
| CN115443271A (zh) | 2022-12-06 |
| CA3174222A1 (en) | 2021-10-14 |
| WO2021207210A1 (en) | 2021-10-14 |
| TW202204348A (zh) | 2022-02-01 |
| EP4132922A4 (en) | 2024-07-03 |
| JP2026097919A (ja) | 2026-06-16 |
| US20260217695A1 (en) | 2026-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019797A2 (pt) | Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo | |
| EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
| IL318601A (en) | Improved synthesis of a key intermediate of the KRAS inhibitor compound G12C | |
| PE20211756A1 (es) | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß | |
| BRPI0710199A2 (pt) | Processo para preparação de inibidores de hiv protease | |
| AU2011295724A8 (en) | 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as NAMPT inhibitors for therapy of diseases such as cancer | |
| CO6311107A2 (es) | Moduladores de inflamacion antioxidantes derivados del acido oleanolico con homologacion c-17 | |
| MX2013002461A (es) | Compuestos y composiciones novedosos para la inhibición de nampt. | |
| BRPI0915692B8 (pt) | compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos | |
| MX2019011778A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| MX2013012760A (es) | Nuevos compuestos y composiciones para la inhibicion de nampt. | |
| BR112023000029A2 (pt) | Método de preparação do composto de fenilisoxazolina | |
| AR121018A1 (es) | Forma en estado sólido de piroxasulfona | |
| CL2011000296A1 (es) | Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados. | |
| MX2023004791A (es) | Sintesis del cocristal 1:1:1 de 1-ciano-2-(4-ciclopropil-bencil)-4 -(beta-d-glucopiranos-1-il)-benceno, l-prolina y agua. | |
| MX2023000970A (es) | Metodo de preparacion de aminofuranos. | |
| MX2025000971A (es) | Proceso para la sintesis del acido (s)-3-amino-4-(difluorometilenil)ciclopent-1-eno-1-carboxilico | |
| CR20110107A (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida (ms-275) | |
| AU2018316542A1 (en) | Indole derivatives as histone demethylase inhibitors | |
| CL2008003059A1 (es) | Metodo para preparar tigeciclina por formacion de un compuesto intermediario nitrado en presencia de una gas inerte y con aislacion de dicho intermediario | |
| PH12021550144A1 (en) | Process and intermediates for the preparation of bilastine | |
| MX2025006444A (es) | Proceso para la sintesis de moduladores de tetrahidrofurano sustituidos de los canales de sodio | |
| CL2023001049A1 (es) | Procedimiento para la fabricación de compuestos orgánicos | |
| MX2022006320A (es) | Composicion para la inhibicion de la produccion de hmf que comprende disacarido de alulosa. | |
| BR112021025588A2 (pt) | Processo para a preparação dos inibidores de canal de cloreto clc-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 401/12 Ipc: C07D 401/12 (2006.01), A61P 35/00 (2006.01) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |